Nasdaq Delisting

Business

AstraZeneca Shifts Gears: Full NYSE Listing Marks Strategic Pivot to US Market

The UK pharmaceutical giant AstraZeneca begins trading ordinary shares on the New York Stock Exchange today, a significant upgrade from its previous Nasdaq ADR listing. This move underscores the company's strategic rebalancing towards the United States, its largest market, and raises questions about the long-term relevance of its London listing.

Feb 2, 2026

Business

ABIVAX Shares Surge on Takeover Buzz and Pipeline Progress, Despite CEO Denials

ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.

Feb 2, 2026

Business

iRhythm Completes Corporate Overhaul, Establishes New Holding Company Structure

Cardiac monitoring specialist iRhythm has finalized a significant corporate restructuring, creating a new parent company to serve as its publicly listed entity on Nasdaq. The move is seen as a strategic step to streamline governance and provide operational flexibility as the company expands its AI-driven health platform.

Feb 2, 2026

Business

Marzetti's Q4 Earnings: Can the Specialty Food Maker Sustain Momentum Amid Slowing Growth?

The Marzetti Company (NASDAQ:MZTI) is set to report fourth-quarter earnings before Tuesday's market open. Investors will scrutinize whether the maker of dressings and sauces can maintain its recent revenue beats amid a projected slowdown in growth and persistent margin pressures.

Feb 2, 2026

Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...

Jan 31, 2026

Business

Day One Biopharmaceuticals: Surging Momentum Raises Valuation Questions Amid High-Stakes Pipeline

Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.

Jan 31, 2026

Business

InterDigital Projects Robust Growth Through 2026, Bolstered by New LG Electronics Pact

InterDigital (NASDAQ: IDCC) has laid out an ambitious financial roadmap for fiscal year 2026, forecasting revenues up to $775 million. The outlook is supported by a newly inked licensing agreement with LG Electronics and a key smartphone renewal, signaling strong momentum in its patent portfolio.

Jan 30, 2026

Business

Rigetti Computing Stock Upgraded to 'Buy' by B. Riley Following Major Quantum Computer Order from India

B. Riley analyst Craig Ellis has upgraded Rigetti Computing (NASDAQ: RGTI) from 'Neutral' to 'Buy', maintaining a $35 price target. The upgrade follows the company's announcement of an $8.4 million order to supply a 108-qubit quantum computer to India's premier R&D agency, C-DAC, providing clearer visibility into its 2026 commercial trajectory.

Jan 30, 2026

Business

USA Rare Earth Secures Major CHIPS Act Funding, Prompting Analyst Price Target Surge

USA Rare Earth Inc. (NASDAQ: USAR) sees its price target significantly raised by Canaccord Genuity and Benchmark following a landmark $1.6 billion commitment from the U.S. CHIPS Program, accelerating its plans to build a domestic rare earth supply chain.

Jan 30, 2026

Business

Analysts Bullish on Ovid Therapeutics as Pipeline Progresses, Penny Stock Gains Attention

Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.

Jan 30, 2026

Business

South Plains Financial Boosts Dividend Payout, Signaling Confidence Amid Growth Trajectory

South Plains Financial (NASDAQ: SPFI) announces an increased quarterly dividend to $0.17 per share, reflecting strong earnings growth and a conservative payout strategy. While the yield remains modest, analysts highlight the company's potential for sustained dividend expansion.

Jan 30, 2026

Business

Independent Bank Boosts Dividend to $0.28, Signaling Financial Strength and Shareholder Commitment

Independent Bank Corporation (NASDAQ: IBCP) announces a dividend increase to $0.28 per share, continuing its decade-long track record of shareholder returns. Analysts highlight the payout's sustainability amid solid earnings growth projections.

Jan 30, 2026

Business

Bitcoin's Exodus: Major Miner Bit Digital Joins Industry Shift Away from Crypto Mining

In a significant industry pivot, Nasdaq-listed Bit Digital announces plans to completely exit Bitcoin mining, citing capital inefficiency and redirecting focus to Ethereum infrastructure and AI. This move follows a broader trend of crypto firms abandoning mining operations post-halving and amidst the AI boom.

Jan 30, 2026

Business

Karat Packaging's Steady Returns Draw Investor Scrutiny Amid Growth Questions

Karat Packaging Inc. (NASDAQ: KRT) showcases a consistent 18% return on capital employed, outperforming its industry. Yet, as capital investment grows, analysts debate whether the sustainable packaging firm can accelerate value creation for shareholders seeking multi-bagger potential.

Jan 30, 2026

Business

Grid Dynamics' Paradox: Soaring Earnings Fail to Halt Stock Slide

Despite a staggering 425% surge in earnings per share over the past year, shareholders of Grid Dynamics Holdings (NASDAQ: GDYN) have watched the stock price plummet 64%. This disconnect between robust financial performance and market valuation highlights the complex forces driving investor sentiment beyond the fundamentals.

Jan 30, 2026

Business

Wall Street Bets on SharpLink Gaming: Analysts See Upside Despite Crypto Volatility

SharpLink Gaming (NASDAQ: SBET) is drawing bullish attention from major Wall Street firms, with multiple analysts reiterating Buy ratings. The company's substantial Ethereum holdings and management's crypto expertise are seen as key drivers, even as price targets adjust to market conditions.

Jan 30, 2026

Business

Innodata Secures Key U.S. Missile Defense Agency Contract, Bolstering AI and Data Services Portfolio

Innodata Inc. (NASDAQ: INOD), a data engineering and AI services firm, has been awarded a place on a critical U.S. Missile Defense Agency contract vehicle, positioning it for future task orders in defense technology development and fueling analyst optimism for its 2026 growth trajectory.

Jan 30, 2026

Business

Immunocore Gains Analyst Backing as Late-Stage Trials Loom

Immunocore Holdings (NASDAQ: IMCR) has drawn renewed bullish sentiment from analysts at H.C. Wainwright and UBS, who highlight the stock's potential as key Phase 3 trial data for its cancer immunotherapies approaches later this decade.

Jan 30, 2026

Business

Digital Turbine Stock Soars 116% in a Year, Defying Recent Slump and Profitability Concerns

Despite a recent 13% quarterly dip, Digital Turbine (NASDAQ: APPS) has delivered a staggering 116% return to investors over the past twelve months. This surge comes even as the mobile software company remains unprofitable, raising questions about the drivers behind its market optimism and its long-term trajectory.

Jan 30, 2026

Business

Benchmark Names T-Mobile (TMUS) a 2026 Best Idea

T-Mobile US Inc. (NASDAQ:TMUS) ranks among the most promising QQQ stocks according to hedge funds. On January 21, Benchmark reaffirmed its Buy rating on T-Mobile US Inc. (NASDAQ:TMUS) with a $295 price target, classifying the telecom provider as a “2026 Benchmark Best Idea.” The firm remains confident that T-Mobile’s network strengths and potential for expanded […]

Jan 30, 2026